A landmark study led by University College London (UCL) has provided compelling evidence that the integration of genomic testing into routine clinical practice can significantly improve the quality of life for breast cancer patients while simultaneously easing the financial burden on the UK’s National Health Service (NHS).
The findings, presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, underscore the clinical utility of Veracyte’s Prosigna assay. By accurately identifying which patients with early-stage, hormone-sensitive breast cancer can safely forgo chemotherapy, the medical community is moving toward a future of "de-escalation"—a strategy that prioritizes patient well-being by avoiding the harsh, often unnecessary toxicities of cytotoxic treatments.
Main Facts: The Power of the PAM50 Signature
At the heart of this medical advancement is the Prosigna assay, a diagnostic tool that analyzes the activity of 50 specific genes, collectively known as the PAM50 signature. By examining the biological profile of breast tumour tissue, the test generates a numerical Risk of Recurrence (ROR) score. This score serves as a prognostic compass, predicting the statistical likelihood of cancer returning in a distant site within a decade of diagnosis.
The clinical significance of this test cannot be overstated. Standard treatment for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer often involves a combination of endocrine (hormone) therapy and systemic chemotherapy. While chemotherapy is a life-saving intervention for many, it carries significant physical, psychological, and financial costs. The OPTIMA trial has demonstrated that for a vast majority of patients with a low ROR score, hormone therapy alone provides outcomes that are non-inferior to the aggressive "chemo-endocrine" standard of care.
The OPTIMA Trial: A Chronology of Evidence
The journey toward these findings began with the design of the OPTIMA trial (ISRCTN42400492), a robust, randomized study aimed at challenging the status quo of breast cancer treatment.
- Trial Initiation and Scope: The study enrolled 4,429 patients diagnosed with HR+/HER2- breast cancer. The inclusion criteria were specific and rigorous, focusing on patients whose cancer had either spread to up to nine lymph nodes or presented with a tumor size of 30mm or greater.
- Initial Data Disclosure (May 2026): Preliminary results were first shared at the American Society of Clinical Oncology (ASCO) Annual Meeting. The data revealed that 67% of patients with a low ROR score were candidates for endocrine therapy alone, sparing them from the debilitating side effects of chemotherapy.
- Five-Year Milestone: Long-term follow-up data presented at ASCO showed remarkable consistency: 93.6% of patients treated with hormone therapy alone remained alive and recurrence-free after five years. This compared favorably to the 94.8% survival rate in the control group, who underwent standard chemotherapy followed by endocrine therapy (CET).
- Economic Analysis (October 2026): Building on the clinical success, the economic analysis presented at ESMO in Madrid crystallized the financial argument for wider adoption, estimating a potential annual saving of £4 million ($5.3 million) for the NHS.
Supporting Data: Why "Less is More"
The economic and clinical implications are deeply intertwined. According to the analysis led by Professor Peter Hall of the University of Edinburgh, the cost-benefit ratio of the Prosigna test is highly favorable.
The Cost Breakdown
- Chemotherapy Expenditure: The standard treatment regimen costs the NHS approximately £5,500 per patient.
- Diagnostic Investment: The Prosigna test requires an expenditure of roughly £1,955 per patient.
- The Net Savings: By utilizing the test to identify low-risk patients, the NHS effectively avoids the £5,500 chemotherapy cost, resulting in a net reduction of £3,611 per patient tested.
When researchers factored in the costs associated with potential secondary treatments for those who skip chemotherapy, the net saving remained substantial at £654 per patient over the first two years. When scaled across the eligible population of the UK—where roughly 6,159 patients meet the specific criteria studied in the OPTIMA trial—the cumulative savings reach £4 million annually.
Official Responses and Expert Perspectives
The academic and clinical community has reacted with cautious optimism, viewing these results as a validation of the precision medicine model.
Dr. Rob Stein, Professor of Breast Oncology at UCL and the Chief Investigator of the OPTIMA trial, highlighted the dual benefit of the study. "This analysis reveals that the trial not only shows Prosigna testing allows about two-thirds of patients with oestrogen-sensitive breast cancer to safely avoid chemotherapy, but doing so also saves the NHS money," Dr. Stein stated during the ESMO conference.
He further emphasized that the £4 million figure is likely a conservative estimate. "This study only looks at about the first two years from diagnosis. We expect cost savings will be greater when we look at the longer term because of the effect of rare, expensive-to-treat, late chemotherapy side effects." By reducing the incidence of long-term complications, such as cardiac damage or secondary malignancies caused by certain chemotherapy agents, the NHS stands to save significantly more than the current projections suggest.
Broader Implications for Healthcare Systems
The shift toward genomic testing represents a fundamental change in how oncology departments approach patient care.
1. Reducing Toxicity and Improving Quality of Life
Chemotherapy is notorious for its side effects, including hair loss, extreme fatigue, nausea, and increased risk of infection. For patients who would not derive a significant survival benefit from chemotherapy, these side effects are essentially "unnecessary toxicity." By using Prosigna to identify this group, clinicians can provide a more compassionate care pathway that focuses on the patient’s quality of life without compromising their survival probability.
2. Regulatory Path and Accessibility
The regulatory history of Prosigna in the UK illustrates a steady integration into the NHS. Initially approved by the National Institute for Health and Care Excellence (NICE) in December 2018, the assay has seen its clinical scope expanded. In May 2024, NICE granted updated clearance to include a broader demographic, including post-menopausal women, men, and trans/non-binary individuals with both lymph node-negative and certain lymph node-positive HR+/HER2- early breast cancers. This reflects an ongoing effort to ensure that the benefits of precision medicine are accessible to a diverse range of patients.
3. Sustainability of the NHS
With the global increase in cancer diagnoses, the NHS is under constant pressure to deliver high-quality care while managing constrained budgets. This study provides a blueprint for how diagnostic innovation can be self-funding. By investing in up-front genomic testing, the healthcare system can optimize its resources, reallocating funds saved from unnecessary chemotherapy toward other vital services, such as immunotherapy or advanced radiotherapy, which may be more appropriate for high-risk patients.
Conclusion: A Paradigm Shift in Breast Cancer Care
The OPTIMA trial and the subsequent economic analysis presented at ESMO 2026 represent more than just a statistical success; they represent a significant step forward in the humanization of cancer treatment.
As the medical field continues to embrace genomic assays like Prosigna, the goal is clear: move away from "one-size-fits-all" treatment protocols toward personalized strategies that reflect the unique biological signature of each patient’s tumor. For the thousands of women diagnosed with early-stage breast cancer in the UK every year, this means the possibility of a shorter, less traumatic treatment journey, while for the NHS, it represents a sustainable path toward better, more efficient oncology care.
As researchers continue to monitor the long-term data, the medical community expects that the value of such tests will only grow, cementing genomic diagnostics as an indispensable pillar of modern cancer medicine.
About the Author
